Tepezza, an FDA-approved drug prescribed for Thyroid Eye Disease (TED), is at the center of a growing wave of lawsuits due to serious allegations of permanent hearing loss linked to the treatment. Many patients have come forward with reports of severe auditory issues, including sensorineural hearing loss and persistent tinnitus, after receiving Tepezza infusions. These claims assert that Horizon Therapeutics, the manufacturer, failed to adequately warn the public and healthcare professionals about the medication’s potential to cause lasting hearing damage—even though early signs surfaced during clinical trials and post-market usage.

To manage the growing volume of claims, Tepezza lawsuits have been consolidated into multidistrict litigation (MDL) in the Northern District of Illinois. This legal structure enables a more efficient handling of shared discovery processes, medical records, and regulatory documents, allowing plaintiffs—either as part of a class action or through individual lawsuits—to seek justice for the damages suffered.

Attorneys across the country are now representing affected individuals, offering free consultations to evaluate claims related to Tepezza-induced hearing impairment. These efforts could ultimately influence how future drugs are tested, labeled, and monitored, reinforcing the importance of transparent communication and rigorous safety standards within the pharmaceutical industry.